Ascentage Pharma Group International Financials
This page shows Ascentage Pharma Group International (AAPG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Ascentage Pharma Group International carries a low D/E ratio of 0.08, meaning only $0.08 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Ascentage Pharma Group International's current ratio of 1.26 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 21/100, which could limit financial flexibility.
While Ascentage Pharma Group International generated -$15.3M in operating cash flow, capex of $3.3M consumed most of it, leaving -$18.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Ascentage Pharma Group International generates a -148.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
For every $1 of reported earnings, Ascentage Pharma Group International generates $0.27 in operating cash flow (-$15.3M OCF vs -$55.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Ascentage Pharma Group International generated $134.3M in revenue in fiscal year 2024.
Ascentage Pharma Group International reported -$55.6M in net income in fiscal year 2024.
Cash & Balance Sheet
Ascentage Pharma Group International generated -$18.6M in free cash flow in fiscal year 2024, representing cash available after capex.
Ascentage Pharma Group International held $122.4M in cash against $2.8M in long-term debt as of fiscal year 2024.
Margins & Returns
Ascentage Pharma Group International's net profit margin was -41.4% in fiscal year 2024, showing the share of revenue converted to profit.
Ascentage Pharma Group International's ROE was -148.0% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Ascentage Pharma Group International invested $3.3M in capex in fiscal year 2024, funding long-term assets and infrastructure.
AAPG Income Statement
| Metric | Q4'24 |
|---|---|
| Revenue | N/A |
| Cost of Revenue | N/A |
| Gross Profit | N/A |
| R&D Expenses | N/A |
| SG&A Expenses | N/A |
| Operating Income | N/A |
| Interest Expense | N/A |
| Income Tax | N/A |
| Net Income | N/A |
| EPS (Diluted) | N/A |
AAPG Balance Sheet
| Metric | Q4'24 |
|---|---|
| Total Assets | $358.6M |
| Current Assets | $202.0M |
| Cash & Equivalents | $122.4M |
| Inventory | $904K |
| Accounts Receivable | $11.4M |
| Goodwill | $3.4M |
| Total Liabilities | $321.1M |
| Current Liabilities | $159.8M |
| Long-Term Debt | $2.8M |
| Total Equity | $37.6M |
| Retained Earnings | N/A |
AAPG Cash Flow Statement
| Metric | Q4'24 |
|---|---|
| Operating Cash Flow | N/A |
| Capital Expenditures | N/A |
| Free Cash Flow | N/A |
| Investing Cash Flow | N/A |
| Financing Cash Flow | N/A |
| Dividends Paid | N/A |
| Share Buybacks | N/A |
AAPG Financial Ratios
| Metric | Q4'24 |
|---|---|
| Gross Margin | N/A |
| Operating Margin | N/A |
| Net Margin | N/A |
| Return on Equity | N/A |
| Return on Assets | N/A |
| Current Ratio | 1.26 |
| Debt-to-Equity | 0.08 |
| FCF Margin | N/A |
Similar Companies
Frequently Asked Questions
What is Ascentage Pharma Group International's annual revenue?
Ascentage Pharma Group International (AAPG) reported $134.3M in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Ascentage Pharma Group International profitable?
No, Ascentage Pharma Group International (AAPG) reported a net income of -$55.6M in fiscal year 2024, with a net profit margin of -41.4%.
How much debt does Ascentage Pharma Group International have?
As of fiscal year 2024, Ascentage Pharma Group International (AAPG) had $122.4M in cash and equivalents against $2.8M in long-term debt.
What is Ascentage Pharma Group International's net profit margin?
Ascentage Pharma Group International (AAPG) had a net profit margin of -41.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Ascentage Pharma Group International's return on equity (ROE)?
Ascentage Pharma Group International (AAPG) has a return on equity of -148.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Ascentage Pharma Group International's free cash flow?
Ascentage Pharma Group International (AAPG) generated -$18.6M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ascentage Pharma Group International's operating cash flow?
Ascentage Pharma Group International (AAPG) generated -$15.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Ascentage Pharma Group International's total assets?
Ascentage Pharma Group International (AAPG) had $358.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Ascentage Pharma Group International's capital expenditures?
Ascentage Pharma Group International (AAPG) invested $3.3M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
What is Ascentage Pharma Group International's current ratio?
Ascentage Pharma Group International (AAPG) had a current ratio of 1.26 as of fiscal year 2024, which is considered adequate.
What is Ascentage Pharma Group International's debt-to-equity ratio?
Ascentage Pharma Group International (AAPG) had a debt-to-equity ratio of 0.08 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ascentage Pharma Group International's return on assets (ROA)?
Ascentage Pharma Group International (AAPG) had a return on assets of -15.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Ascentage Pharma Group International's cash runway?
Based on fiscal year 2024 data, Ascentage Pharma Group International (AAPG) had $122.4M in cash against an annual operating cash burn of $15.3M. This gives an estimated cash runway of approximately 96 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Are Ascentage Pharma Group International's earnings high quality?
Ascentage Pharma Group International (AAPG) has an earnings quality ratio of 0.27x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Ascentage Pharma Group International?
Ascentage Pharma Group International (AAPG) scores 30 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.